NYSE:BIO.B

Bio-Rad Laboratories Competitors

$600.87
+21.49 (+3.71 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$600.87
Now: $600.87
$600.87
50-Day Range
$579.38
MA: $595.60
$664.95
52-Week Range
$321.42
Now: $600.87
$538.00
Volume218 shs
Average Volume94 shs
Market Capitalization$17.92 billion
P/E Ratio5.14
Dividend YieldN/A
Beta0.73

Competitors

Bio-Rad Laboratories (NYSE:BIO.B) Vs. ILMN, A, MTD, TXG, WAT, and AVTR

Should you be buying BIO.B stock or one of its competitors? Companies in the industry of "analytical instruments" are considered alternatives and competitors to Bio-Rad Laboratories, including Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), 10x Genomics (TXG), Waters (WAT), and Avantor (AVTR).

Bio-Rad Laboratories (NYSE:BIO.B) and Illumina (NASDAQ:ILMN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations and risk.

Institutional and Insider Ownership

0.1% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 0.4% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Bio-Rad Laboratories and Illumina's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Rad Laboratories147.91%3.77%2.74%
Illumina19.70%15.93%10.09%

Volatility and Risk

Bio-Rad Laboratories has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.

Earnings & Valuation

This table compares Bio-Rad Laboratories and Illumina's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.31 billion7.75$1.76 billionN/AN/A
Illumina$3.54 billion16.43$1.00 billion$6.5760.73

Bio-Rad Laboratories has higher earnings, but lower revenue than Illumina.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Bio-Rad Laboratories and Illumina, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Rad Laboratories0000N/A
Illumina48602.11

Illumina has a consensus target price of $370.5789, suggesting a potential downside of 7.12%. Given Illumina's higher probable upside, analysts clearly believe Illumina is more favorable than Bio-Rad Laboratories.

Summary

Illumina beats Bio-Rad Laboratories on 9 of the 12 factors compared between the two stocks.

Agilent Technologies (NYSE:A) and Bio-Rad Laboratories (NYSE:BIO.B) are both large-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.

Volatility and Risk

Agilent Technologies has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.

Profitability

This table compares Agilent Technologies and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Agilent Technologies13.47%21.02%10.73%
Bio-Rad Laboratories147.91%3.77%2.74%

Earnings and Valuation

This table compares Agilent Technologies and Bio-Rad Laboratories' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agilent Technologies$5.34 billion7.49$719 million$3.2840.02
Bio-Rad Laboratories$2.31 billion7.75$1.76 billionN/AN/A

Bio-Rad Laboratories has lower revenue, but higher earnings than Agilent Technologies.

Insider and Institutional Ownership

0.1% of Bio-Rad Laboratories shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Agilent Technologies and Bio-Rad Laboratories, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Agilent Technologies081902.70
Bio-Rad Laboratories0000N/A

Agilent Technologies currently has a consensus price target of $104.70, suggesting a potential downside of 20.24%. Given Agilent Technologies' higher probable upside, equities research analysts clearly believe Agilent Technologies is more favorable than Bio-Rad Laboratories.

Summary

Agilent Technologies beats Bio-Rad Laboratories on 7 of the 12 factors compared between the two stocks.

Mettler-Toledo International (NYSE:MTD) and Bio-Rad Laboratories (NYSE:BIO.B) are both large-cap computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Mettler-Toledo International and Bio-Rad Laboratories, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mettler-Toledo International35101.78
Bio-Rad Laboratories0000N/A

Mettler-Toledo International presently has a consensus target price of $971.3750, indicating a potential downside of 20.30%. Given Mettler-Toledo International's higher possible upside, analysts plainly believe Mettler-Toledo International is more favorable than Bio-Rad Laboratories.

Valuation and Earnings

This table compares Mettler-Toledo International and Bio-Rad Laboratories' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mettler-Toledo International$3.01 billion9.45$561.11 million$22.7753.53
Bio-Rad Laboratories$2.31 billion7.75$1.76 billionN/AN/A

Bio-Rad Laboratories has lower revenue, but higher earnings than Mettler-Toledo International.

Volatility and Risk

Mettler-Toledo International has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.

Institutional & Insider Ownership

93.2% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 0.1% of Bio-Rad Laboratories shares are owned by institutional investors. 3.2% of Mettler-Toledo International shares are owned by company insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Mettler-Toledo International and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mettler-Toledo International19.36%144.89%21.11%
Bio-Rad Laboratories147.91%3.77%2.74%

Summary

Mettler-Toledo International beats Bio-Rad Laboratories on 9 of the 12 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO.B) and 10x Genomics (NASDAQ:TXG) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Bio-Rad Laboratories and 10x Genomics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Rad Laboratories0000N/A
10x Genomics01702.88

10x Genomics has a consensus target price of $181.4444, indicating a potential downside of 3.65%. Given 10x Genomics' higher probable upside, analysts plainly believe 10x Genomics is more favorable than Bio-Rad Laboratories.

Institutional and Insider Ownership

0.1% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 68.8% of 10x Genomics shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 13.3% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Bio-Rad Laboratories has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.

Valuation and Earnings

This table compares Bio-Rad Laboratories and 10x Genomics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.31 billion7.75$1.76 billionN/AN/A
10x Genomics$245.89 million83.29$-31,250,000.00($0.80)-235.39

Bio-Rad Laboratories has higher revenue and earnings than 10x Genomics.

Profitability

This table compares Bio-Rad Laboratories and 10x Genomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Rad Laboratories147.91%3.77%2.74%
10x Genomics-51.27%-19.98%-14.38%

Summary

Bio-Rad Laboratories beats 10x Genomics on 7 of the 12 factors compared between the two stocks.

Waters (NYSE:WAT) and Bio-Rad Laboratories (NYSE:BIO.B) are both large-cap computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Profitability

This table compares Waters and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Waters22.61%-349.31%21.11%
Bio-Rad Laboratories147.91%3.77%2.74%

Insider and Institutional Ownership

91.8% of Waters shares are owned by institutional investors. Comparatively, 0.1% of Bio-Rad Laboratories shares are owned by institutional investors. 1.5% of Waters shares are owned by company insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Waters and Bio-Rad Laboratories, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Waters48101.77
Bio-Rad Laboratories0000N/A

Waters presently has a consensus price target of $224.20, suggesting a potential downside of 26.98%. Given Waters' higher possible upside, analysts clearly believe Waters is more favorable than Bio-Rad Laboratories.

Valuation & Earnings

This table compares Waters and Bio-Rad Laboratories' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waters$2.41 billion7.92$592.20 million$8.9934.15
Bio-Rad Laboratories$2.31 billion7.75$1.76 billionN/AN/A

Bio-Rad Laboratories has lower revenue, but higher earnings than Waters.

Volatility and Risk

Waters has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.

Summary

Waters beats Bio-Rad Laboratories on 8 of the 12 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO.B) and Avantor (NYSE:AVTR) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Risk & Volatility

Bio-Rad Laboratories has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Avantor has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500.

Profitability

This table compares Bio-Rad Laboratories and Avantor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Rad Laboratories147.91%3.77%2.74%
Avantor2.21%44.58%6.85%

Analyst Ratings

This is a summary of recent ratings and price targets for Bio-Rad Laboratories and Avantor, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Rad Laboratories0000N/A
Avantor021402.88

Avantor has a consensus target price of $29.7941, suggesting a potential downside of 9.63%. Given Avantor's higher probable upside, analysts clearly believe Avantor is more favorable than Bio-Rad Laboratories.

Institutional & Insider Ownership

0.1% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 84.8% of Avantor shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 1.9% of Avantor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Bio-Rad Laboratories and Avantor's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.31 billion7.75$1.76 billionN/AN/A
Avantor$6.04 billion3.14$37.80 million$0.5856.84

Bio-Rad Laboratories has higher earnings, but lower revenue than Avantor.

Summary

Avantor beats Bio-Rad Laboratories on 8 of the 12 factors compared between the two stocks.


Bio-Rad Laboratories Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Illumina logo
ILMN
Illumina
1.6$398.99+1.1%$58.21 billion$3.54 billion92.57
Agilent Technologies logo
A
Agilent Technologies
1.8$131.27+0.5%$40.00 billion$5.34 billion57.07Insider Selling
Mettler-Toledo International logo
MTD
Mettler-Toledo International
1.3$1,218.84+0.3%$28.42 billion$3.01 billion51.28
10x Genomics logo
TXG
10x Genomics
1.6$188.31+3.4%$20.48 billion$245.89 million-139.49Increase in Short Interest
Waters logo
WAT
Waters
1.3$307.04+0.0%$19.05 billion$2.41 billion38.24
Avantor logo
AVTR
Avantor
1.8$32.97+3.8%$18.95 billion$6.04 billion274.75News Coverage
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$603.99+0.2%$18.03 billion$2.31 billion5.17
PerkinElmer logo
PKI
PerkinElmer
1.9$132.62+0.6%$14.86 billion$2.88 billion36.04
Bruker logo
BRKR
Bruker
1.9$67.65+1.4%$10.25 billion$2.07 billion66.32
Coherent logo
COHR
Coherent
1.5$267.32+0.7%$6.54 billion$1.23 billion-15.55Increase in Short Interest
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.6$30.74+4.6%$5.94 billion$90.89 million-109.78
Berkeley Lights logo
BLI
Berkeley Lights
1.4$47.64+0.8%$3.16 billionN/A0.00
Quanterix logo
QTRX
Quanterix
1.4$62.08+6.5%$2.25 billion$56.73 million-54.94
Bionano Genomics logo
BNGO
Bionano Genomics
1.1$6.74+8.2%$1.88 billion$10.13 million-3.55
Accelerate Diagnostics logo
AXDX
Accelerate Diagnostics
1.8$8.32+6.6%$509.40 million$9.30 million-5.70
Fluidigm logo
FLDM
Fluidigm
1.8$4.61+0.2%$343.66 million$117.24 million-6.88
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.8$6.60+1.1%$262.85 million$116.18 million-36.67
EyePoint Pharmaceuticals logo
EYPT
EyePoint Pharmaceuticals
1.4$9.14+9.5%$262.69 million$20.36 million-2.69Increase in Short Interest
Precipio logo
PRPO
Precipio
1.3$1.96+4.6%$35.54 million$3.13 million0.00
HTG Molecular Diagnostics logo
HTGM
HTG Molecular Diagnostics
1.1$4.94+0.4%$30.70 million$19.20 million-1.32Increase in Short Interest
Astrotech logo
ASTC
Astrotech
0.5$1.21+21.5%$29.78 million$490,000.00-0.99High Trading Volume
Increase in Short Interest
News Coverage
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.